Analysts believe Pfizer has more to offer than just Covid-19 vaccines
- Guggenheim analysts initiate coverage of Pfizer with a Buy rating and $36 price target
- Pfizer stock has 29% upside potential
- Shares have underperformed due to inflated expectations around Covid-19 vaccine
- Opportunity for near-term estimates to increase with successful commercialization of other treatments
- Moderna surprises Wall Street with quarterly profit and sales ahead of expectations
Guggenheim analysts have initiated coverage of Pfizer with a Buy rating and a $36 price target. Despite underperforming in recent years due to inflated expectations around its Covid-19 vaccine, Pfizer stock has a potential upside of 29%. The analysts believe that Pfizer has other revenue-generating opportunities, such as treatments for bladder cancer and RSV. They also suggest that successful commercialization of these opportunities could improve investor sentiment and increase longer-term estimates. In comparison, rival vaccine-maker Moderna has surprised Wall Street with better-than-expected quarterly profit and sales. Currently, 40% of analysts covering Pfizer stock have Buy ratings.
Factuality Level: 3
Factuality Justification: The article provides a brief overview of Guggenheim analysts initiating coverage of Pfizer with a Buy rating and $36 price target. It includes some relevant information about Pfizer’s stock performance and potential opportunities beyond Covid-19 vaccines. However, the article lacks depth and context, and it does not provide a comprehensive analysis of the situation. It also contains some repetitive information and does not address potential biases or conflicting viewpoints.
Noise Level: 3
Noise Justification: The article provides a concise analysis of Guggenheim analysts’ coverage initiation of Pfizer, including the reasons behind the Buy rating and price target. It also mentions the performance of Pfizer stock in comparison to the market and other relevant information. The article stays on topic and supports its claims with data and examples. However, it lacks in-depth analysis of long-term trends or consequences of decisions, which prevents it from receiving a higher rating.
Financial Relevance: Yes
Financial Markets Impacted: Pfizer stock
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article discusses the coverage initiation of Pfizer by Guggenheim analysts and the potential for the stock price to increase. It mentions the underperformance of Pfizer stock in recent years and the impact of the coronavirus pandemic on investor expectations. The article also highlights the potential for near-term estimates to increase if Pfizer successfully commercializes other treatments. There is no mention of an extreme event or its impact.
Public Companies: Pfizer (PFE), Moderna (MRNA)
Key People: Vamil Divan (Analyst)
Reported publicly:
www.marketwatch.com 
